BioTime Inc is a clinical-stage biotechnology company. Its objective is the development and commercialization of novel therapies developed with the help of the company's core technology platforms. The core therapeutic technologies are based on pluripotent stem cells that can become any of the cell types in the human body. Pluripotent stem cells have potential applications in many areas of medicine, including several age-related degenerative diseases and conditions for which there presently are no cures. The product portfolio includes Renevia, a potential treatment for HIV-related facial lipoatrophy; AST-VAC1, a cancer immunotherapy; and OpRegen, a potential therapy derived from pluripotent stem cells to treat the dry form of age-related macular degeneration.